Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Watson Pharmaceuticals Inc Receives FDA Approval For Generic Actos


Friday, 26 Oct 2012 04:23pm EDT 

Watson Pharmaceuticals Inc announced that Watson has launched a generic version of Actos (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval on October 26, 2012 from the U.S. Food and Drug Administration (FDA). Watson began shipping the product immediately. 

Company Quote

216.37
0.24 +0.11%
22 Jul 2014